ORGARAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ORGARAN (ORGARAN).
Danaparoid is a low molecular weight heparinoid that exerts its anticoagulant effect by inhibiting factor Xa and, to a lesser extent, factor IIa (thrombin) through binding to antithrombin III and heparin cofactor II.
| Metabolism | Primarily renal excretion; partially metabolized by desulfation and depolymerization. Enzyme involvement is not well characterized. |
| Excretion | Renal: 40-50% as unchanged drug; biliary/fecal: minimal; small amount metabolized via desulfation and N-acetylation. |
| Half-life | Terminal elimination half-life: 18-25 hours (mean ~19 hours) in patients with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe renal failure, CrCl <30 mL/min). |
| Protein binding | Highly bound (>95%) primarily to antithrombin III (ATIII) and to a lesser extent to other plasma proteins; binding is rapid and reversible. |
| Volume of Distribution | 0.2-0.4 L/kg; low Vd indicates limited extravascular distribution, mainly confined to plasma volume. |
| Bioavailability | Subcutaneous: approximately 95-100% (nearly complete) after SC administration; intravenous: 100%. |
| Onset of Action | Subcutaneous: 2-4 hours for anti-Xa activity; intravenous: immediate for therapeutic anticoagulation. |
| Duration of Action | Subcutaneous: 12-16 hours; duration of anticoagulant effect correlates with anti-Xa activity; monitoring recommended in renal impairment due to accumulation. |
| Molecular Weight | 6000 |
Adults: Initial intravenous bolus of 2500 IU (anti-Xa), followed by continuous intravenous infusion of 400 IU/h for 2 hours, then 300 IU/h for 2 hours, then 200 IU/h for 5 days; or subcutaneous injection of 750 IU twice daily. Dose adjusted to maintain anti-Xa levels of 0.5-1.0 IU/mL.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: Contraindicated. GFR 30-50 mL/min: Reduce dose by 25-50% and monitor anti-Xa levels. GFR >50 mL/min: No adjustment required. |
| Liver impairment | Child-Pugh Class B or C: Caution, reduce initial dose by 25-50% and monitor anti-Xa levels. No specific data for Class A. |
| Pediatric use | Safety and efficacy not established; use not recommended under 18 years of age. |
| Geriatric use | Elderly patients (≥65 years) may have increased risk of bleeding; consider dose reduction by 25% and monitor anti-Xa levels closely, especially those with renal impairment. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Organan (danaparoid) should be used during the first trimester only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown no evidence of teratogenicity. |
| 2nd trimester | Same as T1; caution advised. |
| 3rd trimester | Use only if clearly needed. Risk of bleeding during delivery. Consider switching to heparin if anticoagulation required near term. |
Clinical note
Comprehensive clinical and safety monograph for ORGARAN (ORGARAN).
| Placental transfer | Danaparoid does not cross the placenta in significant amounts. In vitro studies using a dually perfused human cotyledon model showed minimal transfer (less than 0.1% of the maternal concentration). |
| Breastfeeding | It is not known whether danaparoid is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Organan is administered to a nursing woman. Discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
Risk of spinal/epidural hematoma in patients receiving neuraxial anesthesia or spinal puncture, which can result in long-term or permanent paralysis.
| Serious Effects |
Major bleedingThrombocytopenia with a positive in vitro test for anti-platelet antibody in the presence of danaparoidHypersensitivity to danaparoid or any component of the formulationSevere hemorrhagic diathesisSevere uncontrolled hypertension
| Precautions | Increased risk of bleeding with recent surgery, trauma, or hemorrhagic conditions, Do not use interchangeably with heparin or low molecular weight heparins, Monitor renal function; dose adjustment required in severe renal impairment, May cause hypersensitivity reactions including anaphylaxis |
| Food/Dietary | No specific food interactions for danaparoid; maintain usual balanced diet. Avoid alcohol in excess due to increased bleeding risk. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - limited data, caution advised. |
| Teratogenic Risk | Danaparoid (ORGARAN) is a low molecular weight heparinoid. Animal studies have not demonstrated teratogenic effects, and there are no adequate well-controlled studies in pregnant women. However, it should be used during pregnancy only if clearly needed. First trimester: no evidence of increased risk. Second and third trimesters: exposure may be associated with maternal bleeding risks but not specific fetal malformations. |
| Fetal Monitoring | Monitor maternal signs of bleeding (e.g., hemoglobin, hematocrit, occult blood). Monitor platelet count periodically due to potential for thrombocytopenia. Fetal monitoring should include standard prenatal assessments; growth and wellbeing monitoring if maternal condition warrants. |
| Fertility Effects | There are no data on the effects of danaparoid on human fertility. Animal studies have not revealed impaired fertility. |
| Clinical Pearls | Monitor anti-Xa activity using danaparoid-specific chromogenic assay; PT/aPTT unreliable. Avoid in HIT with active thromboembolism until acute phase resolved. Cross-reactivity with PF4/heparin antibodies is low but not zero – obtain baseline platelet count and monitor. Discontinue before invasive procedures; half-life ~25 hours. Dose adjustment required in renal impairment (CrCl <30 mL/min). Record body weight for weight-based dosing. |
| Patient Advice | Take this medication exactly as prescribed; it prevents blood clots. · This drug is not a heparin; tell all healthcare providers you are taking it. · Report any unusual bleeding, bruising, or red/dark urine immediately. · Use caution with sharp objects and electric razors; avoid activities that may cause injury. · Do not take aspirin, ibuprofen, or other blood thinners unless directed by your doctor. · Inform your doctor if you have kidney problems, as dose adjustment may be needed. · If you miss a dose, take it as soon as remembered but do not double dose; contact your doctor. |